Parotid Gland Cancer After Surgical Excision: Treatment When Surgery Did Not Achieve Negative Margins
Clinical Scenario
This protocol addresses patients with parotid gland cancer who have completed open surgical excision — partial, superficial, or total parotidectomy — and in whom the goal of negative surgical margins was not achieved, or in whom high-risk pathological features are identified that require further locoregional treatment.
Why This Protocol Is Indicated
The preceding treatment step is open surgical excision of the parotid malignancy. The primary surgical goal is achieving negative margins. When surgery fails to reach that goal — or when pathology reveals additional high-risk features such as positive margins, high-grade histology, perineural invasion, lymph node involvement, or advanced T-stage — a structured next-line approach is required.
Treatment Direction (Partial Overview)
Postoperative radiation therapy — directed at the surgical bed and appropriate nodal regions — is the treatment strategy for this clinical situation. The full protocol specifies the indications, field design, timing requirements, dose targets, and elective neck considerations that govern how this approach is applied.
References
DOI: 10.1200/JCO.21.00449
- Postoperative RT should be offered to patients with tumors with the following features: high-grade tumors, positive margins; perineural invasion; lymph node metastases; lymphatic or vascular invasion; and T3-4 tumors.
- Postoperative RT may be offered to patients with tumors with close margins or intermediate-grade tumors.
- In postoperative cases, the high-dose target should cover the salivary gland surgical bed and appropriate nodal levels.
- Postoperative radiotherapy when conventionally fractionated should be at least 60 Gy to the high-dose target.
- Radiation should be initiated within 8 weeks of surgery.
- In the case of perineural invasion, the associated nerve(s) may be covered with an elective or intermediate dose to the skull base.
- Coverage of the involved nerve to the base of skull with an elective or intermediate dose (46-54 Gy in 2 Gy fractions) may be reasonable to reduce the risk of retrograde nerve failure toward the base of skull.
- Elective neck irradiation may be offered in patients with cN0 disease for the following indications: T3-T4 cancers or high-grade malignancies.
View source ↗